Total submissions: 14
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000726496 | SCV000292720 | uncertain significance | not provided | 2022-09-08 | criteria provided, single submitter | clinical testing | Identified in several unrelated patients with dilated cardiomyopathy, unspecified cardiomyopathy, or sudden cardiac death in published literature; however, no further clinical or segregation information was provided (van Spaendonck-Zwarts et al., 2013; van Lint et al., 2019; Verdonschot et al., 2020); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 25637381, 10939567, 32880476, 23349452, 30847666) |
Eurofins Ntd Llc |
RCV000726496 | SCV000701487 | uncertain significance | not provided | 2016-10-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000653909 | SCV000775799 | uncertain significance | Charcot-Marie-Tooth disease type 2 | 2023-11-27 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 334 of the LMNA protein (p.Ser334Asn). This variant is present in population databases (rs370656306, gnomAD 0.004%). This missense change has been observed in individual(s) with clinical features of LMNA-related conditions (PMID: 23349452, 30847666, 32880476). ClinVar contains an entry for this variant (Variation ID: 161292). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on LMNA protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Color Diagnostics, |
RCV001183553 | SCV001349316 | uncertain significance | Cardiomyopathy | 2023-10-12 | criteria provided, single submitter | clinical testing | This missense variant replaces serine with asparagine at codon 334 of the lamin A/C protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in at least 2 individuals affected with dilated cardiomyopathy (PMID: 23349452, 30847666, 32880476). It has also been reported in individuals affected with unspecified cardiomyopathy and aborted sudden cardiac death (PMID: 30847666). This variant has been identified in 6/281674 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Athena Diagnostics | RCV000726496 | SCV001476533 | uncertain significance | not provided | 2019-09-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002381457 | SCV002693568 | uncertain significance | Cardiovascular phenotype | 2023-08-24 | criteria provided, single submitter | clinical testing | The p.S334N variant (also known as c.1001G>A), located in coding exon 6 of the LMNA gene, results from a G to A substitution at nucleotide position 1001. The serine at codon 334 is replaced by asparagine, an amino acid with highly similar properties. This variant has been detected in several individuals in cardiomyopathy and/or arrhythmia testing cohorts; however, clinical details were limited (van Spaendonck-Zwarts KY et al. Eur J Heart Fail, 2013 Jun;15:628-36; van Lint FHM et al. Neth Heart J, 2019 Jun;27:304-309; Park J et al. Genet Med, 2020 Jan;22:102-111). This amino acid position is not well conserved in available vertebrate species, and asparagine is the reference amino acid in other vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002478412 | SCV002786047 | uncertain significance | Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome; Dilated cardiomyopathy 1A; Charcot-Marie-Tooth disease type 2B1; Emery-Dreifuss muscular dystrophy 2, autosomal dominant; Heart-hand syndrome, Slovenian type; Hutchinson-Gilford syndrome; Familial partial lipodystrophy, Dunnigan type; Mandibuloacral dysplasia with type A lipodystrophy; Congenital muscular dystrophy due to LMNA mutation; Emery-Dreifuss muscular dystrophy 3, autosomal recessive; Restrictive dermopathy 2 | 2021-09-14 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000726496 | SCV003814697 | uncertain significance | not provided | 2019-12-24 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000148605 | SCV004816976 | uncertain significance | Primary dilated cardiomyopathy | 2023-11-02 | criteria provided, single submitter | clinical testing | This missense variant replaces serine with asparagine at codon 334 of the lamin A/C protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in at least 2 individuals affected with dilated cardiomyopathy (PMID: 23349452, 30847666, 32880476). It has also been reported in individuals affected with unspecified cardiomyopathy and aborted sudden cardiac death (PMID: 30847666). This variant has been identified in 6/281674 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
CSER _CC_NCGL, |
RCV000148605 | SCV000190320 | uncertain significance | Primary dilated cardiomyopathy | 2014-06-01 | no assertion criteria provided | research | |
Diagnostic Laboratory, |
RCV000726496 | SCV001741392 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics, |
RCV000726496 | SCV001925650 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000726496 | SCV001929788 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000726496 | SCV001957735 | uncertain significance | not provided | no assertion criteria provided | clinical testing |